- 8, The Green Suite, 12341 Dover,
DE 19901-3618 - info@immgenuity.com
+1-302-321-5844
Immgenuity Inc.
Applying ingenuity and innovation
to improve lives around the world
About Us
Scientific Advisory Board
 Dr. Roscoe Moore |
 Dr. Marcel Curlin |
 Dr. Jürgen Rockstroh |
 Dr. Daniel Kuritzkes |
 Dr. Carol Brosgart |
 Dr. Richard Ogden |
 Dr. Satish Chandran |
 Dr. Ron Sekura |
 Jesse Milan Jr., JD |
 Dr. Jessica Robinson-Papp |
Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. Dr. Moore has been acknowledged as the “Father” of Medical Device Epidemiology by FDA for establishing the first Medical Device Epidemiology Training Fellowship Program within the USPHS. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.
Dr. Moore has international experience with countries of North Africa (Morocco), North West Africa (Mauritania), Sub-Saharan Africa, West Africa (Senegal, Nigeria, and Mali), Central Africa (Central African Republic, Republic of Congo, Rwanda, and Uganda), East Africa (Kenya, Mozambique, and Tanzania) and Southern Africa (South Africa and the countries of the Southern African Development Community [SADC]). He also has experience in England, Israel, Switzerland, Norway, Ireland, Spain, France, Italy, Germany, Austria, the former Yugoslavia (Serbia, Macedonia, and Croatia), Poland, Mexico, Canada, Indonesia, Malaysia, Vietnam, China, and Caribbean Nations (Bahamas, Barbados, Dominican Republic, Haiti, Jamaica, and Puerto Rico). During his career and while on official duty, Dr. Moore has traveled to 44 of the 50 states in the United States of America.
Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues. He is a Fellow of the American College of Epidemiology. Dr. Moore serves on the Board of Trustees for Friends of the University of Stellenbosch Foundation. He is a life-member of Delta Omega, the honorary society in public health at the Johns Hopkins University.
Dr. Curlin received an undergraduate degree from Amherst College in 1989, and a doctorate of medicine from the Oregon Health and Sciences University in 1995. After completing training in Internal Medicine (University of Utah, 1998) and Infectious Diseases (University of Washington, 2002), he remained at the University of Washington to pursue interests in molecular virology and HIV vaccine studies. In 2010, Dr. Curlin joined the US Centers for Disease Control and Prevention and served as the Chief of the HIV/STD laboratory sciences section in Bangkok, Thailand for four years. In 2015 Dr. Curlin returned to OHSU to lead early-phase clinical testing of T-cell based HIV vaccines for the vaccine research program directed by Dr. Louis Picker at the Vaccine and Gene Therapy Institute. Dr. Curlin co-directs development of infectious diseases research collaborations in Southeast Asia for OHSU Global, and is clinically active on the Infectious Diseases Inpatient consultation service.
Dr. Curlin has experience in both clinical and laboratory-based research in HIV. Dr. Curlin research focuses on HIV vaccine development, HIV prevention methods, and basic mechanisms of host-virus interactions during HIV infection.
Dr. Curlin is a specialist in adult infectious diseases including HIV infection. He is currently an Associate Professor of Medicine at OHSU and the Director of OHSU's Occupational Health Infectious Diseases Division.
Dr. Brosgart serves as an independent director on the Boards of both public and privately-held biotechnology companies (Galmed, Abivax,, Enochian, and Intrivo Diagnostics) and previously served on the Boards of Juvaris (now Bayer), Tobira (now Allergan, then AbbVie) until they were acquired; as a consultant to global biopharmaceutical companies (currently Dynavax, Moderna, and Pardes Bio); as a member of the United States Centers for Disease Control (CDC)/Health and Human Services (HHS) Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, and was the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC. She has held numerous senior management positions within biotechnology and health care. Dr. Brosgart was the Chief Medical Officer for Alios BioPharma (now Johnson & Johnson), a biotech company developing therapies to treat viral diseases. Dr. Brosgart joined Alios from UCSF Benioff Children’s Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. For eleven years Dr. Brosgart held a number of senior management positions at Gilead Sciences (Vice President, Clinical Research; Vice President, Medical Affairs; and Vice President, Public Health and Policy). While Vice President of Clinical Research at Gilead she was responsible for the clinical development and approval by the FDA and by regulatory authorities worldwide of two antiviral therapies: Viread® for the treatment of HIV, and Hepsera® for the treatment of Chronic Hepatitis B.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching. She was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV/AIDS.
Dr. Brosgart received her B.S. in Community Medicine from the University of California, Berkeley (UCB), her M.D. from the University of California, San Francisco (UCSF), and her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine (UCB). She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV, and related public health policy. She is Clinical Professor of Medicine, Biostatistics and Epidemiology at UCSF.
Jürgen Rockstroh, MD, is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany.
In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV, hepatitis co-infection and COVID-19.
From 2007-2011 he was elected as the president of the German AIDS Society. Since 2009, he is a member of the executive committee of the European AIDS Clinical Society (EACS) and from 2011-2020 member of the governing council of the International AIDS Society. He also was the chair of the National German AIDS Advisory Panel from 2011-2017 and the EACS coinfection guidelines from 2008-2017. In 2015 Professor Rockstroh was elected chair of HIV in Europe (in 2019 renamed as EuroTEST) and from 2019-2020 president for European AIDS Clinical Society.
Dr Rockstroh has authored or co-authored over 700 publications in peer-reviewed journals, and over 100 book chapters. His department treats the world’s largest cohort of HIV-infected hemophiliacs.
Dr. Ogden joined Agouron Pharmaceuticals, Inc. as a founding scientist at its inception in 1984, where he held positions of Group Leader of Medicinal Chemistry, Principal Scientist, and Senior Director of Scientific Development. He was a team member in the HIV project which led to the discovery and development of Nelfinavir (Viracept®). Responsibilities in Scientific Development included presenting Agouron R&D activities to potential corporate partners and investors, assessing technology and compound acquisitions, organizing the process by which new drug targets were selected and projects initiated, and communicating research and clinical activities to clinicians, other healthcare providers and patient groups.
He served as the scientific liaison for the Agouron/Pfizer commercial and corporate organizations following the merger with Pfizer, and his principal responsibilities have included assisting in the continued support of the protease inhibitor Nelfinavir, by providing medical education, including CME certified presentations, within the HIV/AIDS clinical and patient communities, and in the evaluation of proposals for post marketing clinical research in the HIV/AIDS area. He also supported the pre-marketing activities for many clinical agents in the HIV/AIDS and oncology therapeutic areas. With Pfizer, he had an additional opportunity to work with the Pfizer Foundation in its support of the Academic Alliance and its efforts in Uganda, and with Corporate Philanthropy, in its support of the World Economic Forum and the Global Business Council. He also had the opportunity to advise and brief the CEO, Hank McKinnell, during his membership of the Presidential Advisory Commission on HIV/AIDS. He served with both Agouron and Pfizer as the representative on the International AIDS Society Industry Liaison Forum. In addition to numerous publications, he is co-editor, with Charles Flexner, on a book on Protease Inhibitors in AIDS Therapy and with Gail Skowron, on a book on Reverse Transcriptase Inhibitors in AIDS Therapy.
He received his bachelor’s degree in natural sciences and doctorate in synthetic organic chemistry with Dr. Dan Brown at Cambridge University. His academic career started with postdoctoral research studying RNA transcription and processing at the University of California, San Diego in the laboratory of Professor John Abelson, following which he undertook independent research, funded by the National Science Foundation, in the area of protein and RNA structure-function relationships at the University of California, San Diego and the Agouron Institute.
Dr. Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.
Dr. Kuritzkes has over 600 publications in peer-reviewed scientific journals and his work has been cited over 30,000 times by other researchers. His own research focuses on HIV therapeutics, antiretroviral drug resistance, and HIV persistence and eradication.
Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER).
Dr. Sekura is the former president of Vivonex LLC and Biotechnology Assessment Services, Inc. Dr. Sekura did his undergraduate and masters education in biochemistry at Pennsylvania State University and obtained his PhD from Cornell University. Dr. Sekura is the author of over 75 articles in peer-reviewed journals and co-author of a book on pertussis toxins. /p>
Dr. Sekura is experienced in developing a vaccine and its immunologic properties when he developed an acellular pertussis vaccine.
Dr. Robinson-Papp is a practicing neurologist and clinical researcher. She is a Professor of Neurology, the Director of the Mount Sinai NeuroHIV Program, the PAIRED Project and Autonomic Laboratory. She studies the neurologic complications of HIV including autonomic neuropathy and HIV-associated neurocognitive disorder.
A nationally and internationally recognized researcher, Dr. Robinson-Papp has been funded by multiple grants from the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). Her expertise has been recognized by her inclusion on numerous committees and advisory groups including: the American Academy of Neurology Science Committee, Neurological Sciences Training Review Group, Global HIV Pain Task Force, and Executive Board of the World Federation of Neurology Autonomic Disorders Subspecialty Group.
Clinically, Dr. Robinson-Papp is the senior attending neurologist for the Institute for Advanced Medicine, where she provides neurologic care to people living with HIV and oversees pain management services. In addition, Dr. Robinson-Papp performs electromyography (EMG), autonomic testing, and intraoperative neurologic monitoring, to aid in the diagnosis of neurologic disorders. Dr. Robinson-Papp has numerous articles published in peer-reviewed journals.
Dr. Chandran has had a long career as VP of vaccine manufacturing at Wyeth and Pfizer.
After his retirement from Wyeth, Dr. Chandran has held several leadership positions at early and mid-stage biotech and pharmaceutical companies, is also a board member and CEO of Prodigy Biotech, Inc., in addition to his positions with Lays Sciences, Inc. and Physis Pharma, Inc. In addition to several other executive biopharma roles, Dr. Chandran was the CTO of Pfizer Biotherapeutics. Dr. Chandran was instrumental in the creation of RPK Pharma, Inc., a joint venture between Prodigy Biotech, Inc., Reagene Biosciences Pvt. Ltd., and Kyntox Pvt. Ltd. to develop OTC and medical device products based on IgY technology. Until April 2021, Dr. Chandran was the CTO, President, and COO of Marizyme (OTC: MRZM).
Dr. Chandran has over 30 years of experience in all aspects of biotechnology companies. Dr. Chandran is also the co-author or several peer-reviewed publications.
Mr. Milan is joining in his individual capacity and not on behalf of, or representing any organization. His advice will be his own.
Jesse Milan, Jr., JD is a tireless community advocate and recognized national and international expert on HIV/AIDS policies and programs. Mr. Milan brings over 30 years in executive roles in public and private sectors, including in government, not-for-profit, academic, and faith organizations. During his long career, Mr. Milan has directed multi-million-dollar budgets and programs for federal, state, local, and global health agencies.
Mr. Milan’s exceptional record of public service includes serving currently on the Scientific Advisory Board for the President’s Emergency Plan for AIDS Relief (PEPFAR), on the Infectious Disease Board of the American Board of Internal Medicine, and on the board of AVAC (AIDS Vaccine Advocacy Coalition). He is an officer of the board of directors of Funders Concerned About AIDS (FCAA) and serves on the Dean’s Advisory Council for the UNC Gillings School of Global Public Health.
Mr. Milan chaired the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment for five years. In 2007 he was designated a Fulbright Senior Specialist in Global HIV/AIDS.
Mr. Milan has addressed millions on television and radio and given hundreds of keynote addresses and presentations at national, regional, and global conferences and events. An inspiring speaker, he has conducted three speaking tours as an American expert on HIV to seven African nations on behalf of the U.S. State Department. In 2020, he delivered the opening address to the American Medical Students Association conference and the closing address for HRSA for the 30th anniversary of the Ryan White Program.
Mr. Milan has received numerous honors including the Public Service Award in 2015 from the Association of Nurses in AIDS Care (ANAC) and the 2020 Alexander Forger Award for HIV Advocacy from the American Bar Association.
He is a graduate of Princeton University and the NYU School of Law. He currently serves as President and CEO of AIDS United.